ClinicalTrials.gg
CompletedNCT00612573Updated Apr 22, 2013Results posted

Treatment of Moderate to Severe Facial Acne Vulgaris

A Phase 2 interventional study of Doxycycline 0.6 mg/kg/day and Doxycycline 1.2 mg/kg/day in Acne Vulgaris, sponsored by Warner Chilcott. Completed at 23 sites in United States. Open to participants aged 12 Years to 45 Years. Per ClinicalTrials.gov, last updated 2013-04-22.

Sponsored by Warner Chilcott (part of AbbVie) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
257
Allocation
Randomized
Ages
12 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing doxycycline in Acne Vulgaris — 2 open to participants now, 3 under way, none of them phase 3. Doxycycline · Acne Vulgaris.

Enrollment
2nd of 12
257 · median 47
Started
2008
with 1 other
Phase 2
2 of 12
1 open now
Registered
2nd of 12
by date
Lead sponsor
2 of 12
Warner Chilcott

Among the 12 studies testing doxycycline in Acne Vulgaris, this one is the 2nd largest by enrollment, is one of 2 that started in 2008, is one of 2 in phase 2, and was the 2nd registered.

Acne Vulgaris

791 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.

Browse Acne Vulgaris studies →

Open to participants now

2 of the 12 studies testing doxycycline in Acne Vulgaris are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

About doxycycline

Doxycycline: first FDA approval 1967 (VIBRAMYCIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 46 Acne Vulgaris studies recruiting now, 16 (35%) set no upper age limit and 29 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.

This study: 12 Years to 45 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing doxycycline in Acne Vulgaris, or all of them as a file.
02

Study summary

Randomized, multi-center, double-blind, placebo-controlled 12-week study to assess the safety and efficacy of 3 doses of an oral formulation of Doxycycline oral tablets using the Investigator's Global Assessment (IGA) score and the absolute change from baseline in inflammatory lesion count in patients with moderate to severe facial acne vulgaris. Additionally, the absolute change from baseline in non-inflammatory and total lesions of the active study medication to placebo will be evaluated.

03

Conditions studied

  • Acne Vulgaris

Browse trials for

04

Who can participate

Ages eligible
12 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must be between 12 and 45 years of age.
  • Has a diagnosis of moderate to severe facial acne vulgaris with no more than two nodules on the face

Exclusion criteria

Exclusion Criteria:

  • Is allergic to tetracycline-class antibiotics or to any ingredient in the study medication.
  • Has a history of pseudomembranous colitis or antibiotic-associated colitis.
  • Has a history of hepatitis or liver damage or renal impairment.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
257 participants (actual)

Study arms

  • Experimental
    Doxycyline 0.6 mg/kg/day

    Doxycycline dosed at 40 mg/day to subjects of appropriate weights

    Drug: Doxycycline 0.6 mg/kg/day

  • Experimental
    Doxycycline 1.2 mg/kg/day

    Doxycycline dosed at 80 mg/day to subjects of appropriate weights

    Drug: Doxycycline 1.2 mg/kg/day

  • Experimental
    Doxycycline 2.4 mg/kg/day

    Doxycycline dosed at 160 mg/day to subjects of appropriate weights

    Drug: Doxycycline 2.4 mg/kg/day

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugDoxycycline 0.6 mg/kg/day

    Drug page: Doxycycline

    doxycycline 40 mg/day, oral, 12 weeks

  • DrugDoxycycline 1.2 mg/kg/day

    Drug page: Doxycycline

    doxycycline 80 mg/day, 12 weeks

  • DrugDoxycycline 2.4 mg/kg/day

    Drug page: Doxycycline

    doxycycline 160 mg/day, 12 weeks

  • DrugPlacebo

    Placebo, 12 weeks

06

What researchers measure

Primary outcomes

  1. Percentage Patients With Successful Outcome Investigator's Global Assessment (IGA) Score at Week 12, Intent to Treat (ITT) Population

    IGA: 0/clear (clear skin no lesions, inflammatory or non-inflammatory), 1/almost clear (rare non-inflammatory lesion w/no more than 1 small inflammatory lesion), 2/mild (some non-inflammatory lesions with no more than a few inflammatory lesions, papules/pustules only, no nodular lesions), 3/moderate (up to many non-inflammatory lesions, some inflammatory lesions, no more than 1 small nodular lesion), 4/severe (many non-inflammatory \& inflammatory lesions, no more than a few nodular lesions. Lower score improvement in score. Success=IGA decrease of at least 2 grades from baseline score.

    Time frame: Week 12

  2. Absolute Change in Inflammatory Lesion Count From Baseline to Week 12, ITT Population

    Change derived as Baseline evaluation minus the Week 12 evaluation. Thus a positive change reflects a reduction in lesion count. Inflammatory Lesion Count includes nodules, papules and pustules.

    Time frame: Baseline to Week 12

Secondary outcomes

  1. Absolute Change From Baseline to Week 12 in NonInflammatory Lesion Count, ITT Population

    Noninflammatory Lesion Count includes open and closed comedones.

    Time frame: Baseline to Week 12

  2. Absolute Change From Baseline to Week 12 in Total Lesion Count, ITT Population

    Total Lesion Count is the sum of inflammatory and noninflammatory lesions.

    Time frame: Baseline to Week 12

07

Results

Posted Apr 19, 2011

Participant flow

Recruitment began 4 Mar '08

Participant flow — Overall Study
MilestoneDoxycycline 0.6 mg/kg/DayDoxycycline 1.2 mg/kg/DayDoxycycline 2.4 mg/kg/DayPlacebo Comparator
Started64656167
Completed52515254
Not completed1214913

Outcome measures

PrimaryPercentage Patients With Successful Outcome Investigator's Global Assessment (IGA) Score at Week 12, Intent to Treat (ITT) Population

IGA: 0/clear (clear skin no lesions, inflammatory or non-inflammatory), 1/almost clear (rare non-inflammatory lesion w/no more than 1 small inflammatory lesion), 2/mild (some non-inflammatory lesions with no more than a few inflammatory lesions, papules/pustules only, no nodular lesions), 3/moderate (up to many non-inflammatory lesions, some inflammatory lesions, no more than 1 small nodular lesion), 4/severe (many non-inflammatory \& inflammatory lesions, no more than a few nodular lesions. Lower score improvement in score. Success=IGA decrease of at least 2 grades from baseline score.

Time frame:
Week 12
Reported as:
Number · Percentage of Participants
Percentage Patients With Successful Outcome Investigator's Global Assessment (IGA) Score at Week 12, Intent to Treat (ITT) Population
Percentage of ParticipantsDoxycycline 0.6 mg/kg/DayDoxycycline 1.2 mg/kg/DayDoxycycline 2.4 mg/kg/DayPlacebo Comparator
Percentage Patients With Successful Outcome Investigator's Global Assessment (IGA) Score at Week 12, Intent to Treat (ITT) Population14.1 (6.6 to 25.0)15.4 (7.6 to 26.5)29.5 (18.5 to 42.6)16.4 (8.5 to 27.5)
Statistical analysis
  • Doxycycline 0.6 mg/kg/Day vs Placebo Comparator · Cochran-Mantel-Haenszel · p = 0.779 · Mean change from baseline: -0.75 · 95% CI -14.8 to 10.3Stratified by Investigational Site
  • Doxycycline 1.2 mg/kg/Day vs Placebo Comparator · Cochran-Mantel-Haenszel · p = 0.983 · Mean change from baseline: -0.69 · 95% CI -13.7 to 11.7Stratified by Investigational Site
  • Doxycycline 2.4 mg/kg/Day vs Placebo Comparator · Cochran-Mantel-Haenszel · p = 0.087 · Mean change from baseline: -0.92 · 95% CI -1.5 to 27.3Stratified by Investigational Site
PrimaryAbsolute Change in Inflammatory Lesion Count From Baseline to Week 12, ITT Population

Change derived as Baseline evaluation minus the Week 12 evaluation. Thus a positive change reflects a reduction in lesion count. Inflammatory Lesion Count includes nodules, papules and pustules.

Time frame:
Baseline to Week 12
Reported as:
Mean · Lesions
Absolute Change in Inflammatory Lesion Count From Baseline to Week 12, ITT Population
LesionsDoxycycline 0.6 mg/kg/DayDoxycycline 1.2 mg/kg/DayDoxycycline 2.4 mg/kg/DayPlacebo Comparator
Absolute Change in Inflammatory Lesion Count From Baseline to Week 12, ITT Population8.1 ± 13.211.5 ± 12.114.0 ± 19.77.3 ± 13.8
Statistical analysis
  • Doxycycline 0.6 mg/kg/Day vs Placebo Comparator · Cochran-Mantel-Haenszel · p = 0.807Stratified by Investigational Site
  • Doxycycline 1.2 mg/kg/Day vs Placebo Comparator · Cochran-Mantel-Haenszel · p = 0.075Stratified by Investigational Site
  • Doxycycline 2.4 mg/kg/Day vs Placebo Comparator · Cochran-Mantel-Haenszel · p = 0.039Stratified by Investigational Site
SecondaryAbsolute Change From Baseline to Week 12 in NonInflammatory Lesion Count, ITT Population

Noninflammatory Lesion Count includes open and closed comedones.

Time frame:
Baseline to Week 12
Reported as:
Mean · Lesions
Absolute Change From Baseline to Week 12 in NonInflammatory Lesion Count, ITT Population
LesionsDoxycycline 0.6 mg/kg/DayDoxycycline 1.2 mg/kg/DayDoxycycline 2.4 mg/kg/DayPlacebo Comparator
Absolute Change From Baseline to Week 12 in NonInflammatory Lesion Count, ITT Population8.5 ± 19.15.2 ± 28.16.5 ± 16.21.8 ± 31.0
Statistical analysis
  • Doxycycline 0.6 mg/kg/Day vs Placebo Comparator · Cochran-Mantel-Haenszel · p = 0.212Stratified by Investigational Site
  • Doxycycline 1.2 mg/kg/Day vs Placebo Comparator · Cochran-Mantel-Haenszel · p = 0.505Stratified by Investigational Site
  • Doxycycline 2.4 mg/kg/Day vs Placebo Comparator · Cochran-Mantel-Haenszel · p = 0.399Stratified by Investigational Site
SecondaryAbsolute Change From Baseline to Week 12 in Total Lesion Count, ITT Population

Total Lesion Count is the sum of inflammatory and noninflammatory lesions.

Time frame:
Baseline to Week 12
Reported as:
Mean · Lesions
Absolute Change From Baseline to Week 12 in Total Lesion Count, ITT Population
LesionsDoxycycline 0.6 mg/kg/DayDoxycycline 1.2 mg/kg/DayDoxycycline 2.4 mg/kg/DayPlacebo Comparator
Absolute Change From Baseline to Week 12 in Total Lesion Count, ITT Population16.6 ± 25.616.8 ± 32.720.5 ± 25.09.1 ± 38.1
Statistical analysis
  • Doxycycline 0.6 mg/kg/Day vs Placebo Comparator · Cochran-Mantel-Haenszel · p = 0.276Stratified by Investigational Site
  • Doxycycline 1.2 mg/kg/Day vs Placebo Comparator · Cochran-Mantel-Haenszel · p = 0.231Stratified by Investigational Site
  • Doxycycline 2.4 mg/kg/Day vs Placebo Comparator · Cochran-Mantel-Haenszel · p = 0.081Stratified by Investigational Site

Adverse events

Collected over 4 Mar 2008 thru 6 Nov 2008. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Doxycycline 0.6 mg/kg/Day—0/64 (0%)22/64 (34.4%)
Doxycycline 1.2 mg/kg/Day—0/65 (0%)20/65 (30.8%)
Doxycycline 2.4 mg/kg/Day—0/61 (0%)29/61 (47.5%)
Placebo Comparator—1/67 (1.5%)25/67 (37.3%)
Most frequent serious events
Most frequent serious events
EventDoxycycline 0.6 mg/kg/DayDoxycycline 1.2 mg/kg/DayDoxycycline 2.4 mg/kg/DayPlacebo Comparator
Fracture (Left Radius)Injury, poisoning and procedural complications0/640/650/611/67
Most frequent other events
Showing 10 of 17
Most frequent other events
EventDoxycycline 0.6 mg/kg/DayDoxycycline 1.2 mg/kg/DayDoxycycline 2.4 mg/kg/DayPlacebo Comparator
NauseaGastrointestinal disorders0/641/658/612/67
HeadacheNervous system disorders6/644/654/615/67
VomitingGastrointestinal disorders1/641/654/610/67
SunburnInjury, poisoning and procedural complications0/644/651/611/67
DiarrheaGastrointestinal disorders3/642/652/610/67
Pharyngolaryngeal PainRespiratory, thoracic and mediastinal disorders1/640/651/613/67
GastroenteritisGastrointestinal disorders0/640/652/610/67
MyalgiaMusculoskeletal and connective tissue disorders0/640/652/611/67
NasopharyngitisRespiratory, thoracic and mediastinal disorders1/642/652/612/67
Back PainMusculoskeletal and connective tissue disorders2/640/650/610/67

Baseline characteristics

Age Continuous
Age Continuous(years)Doxycycline 0.6 mg/kg/DayDoxycycline 1.2 mg/kg/DayDoxycycline 2.4 mg/kg/DayPlacebo ComparatorTotal
Mean19.3 ± 5.219.4 ± 6.620.7 ± 7.420.2 ± 7.519.9 ± 6.7
Age, Customized
Age, Customized(Participants)Doxycycline 0.6 mg/kg/DayDoxycycline 1.2 mg/kg/DayDoxycycline 2.4 mg/kg/DayPlacebo ComparatorTotal
>= 18 years32392735133
< 18 years32263432124
Sex: Female, Male
Sex: Female, Male(Participants)Doxycycline 0.6 mg/kg/DayDoxycycline 1.2 mg/kg/DayDoxycycline 2.4 mg/kg/DayPlacebo ComparatorTotal
Female35303635136
Male29352532121
Region of Enrollment
Region of Enrollment(participants)Doxycycline 0.6 mg/kg/DayDoxycycline 1.2 mg/kg/DayDoxycycline 2.4 mg/kg/DayPlacebo ComparatorTotal
United States64656167257
08

Study locations

23 sites
  • Warner Chilcott Investigational Site
    Encino, California 91436, United States
  • Warner Chilcott Investigational Site
    Fremont, California 94538, United States
  • Warner Chilcott Investigational Site
    Los Angeles, California 90045, United States
  • Warner Chilcott Investigational Site
    Sacramento, California 95816, United States
  • Warner Chilcott Investigational Site
    Denver, Colorado 80210, United States
  • Warner Chilcott Investigational Site
    Miami, Florida 33175, United States
  • Warner Chilcott Investigational Site
    Newnan, Georgia 30263, United States
  • Warner Chilcott Investigational Site
    Snellville, Georgia 30078, United States
  • Warner Chilcott Investigational Site
    Louisville, Kentucky 40217, United States
  • Warner Chilcott Investigational Site
    Clinton Township, Michigan 48038, United States
  • Warner Chilcott Investigational Site
    Albuquerque, New Mexico 87106-5239, United States
  • Warner Chilcott Investigational Site
    Rochester, New York 14623, United States
  • Warner Chilcott Investigational Site
    Winston Salem, North Carolina 27103, United States
  • Warner Chilcott Investigational Site
    Cincinnati, Ohio 45219, United States
  • Warner Chilcott Investigational Site
    Portland, Oregon 97210, United States
  • Warner Chilcott Investigational Site
    Broomall, Pennsylvania 19008, United States
  • Warner Chilcott Investigational Site
    Fort Washington, Pennsylvania 19034, United States
  • Warner Chilcott Investigational Site
    Austin, Texas 78759, United States
  • Warner Chilcott Investigational Site
    College Station, Texas 77845, United States
  • Warner Chilcott Investigational Site
    Dallas, Texas 75246, United States
  • Warner Chilcott Investigational Site
    Houston, Texas 77056, United States
  • Warner Chilcott Investigational Site
    San Antonio, Texas 78229, United States
  • Warner Chilcott Investigational Site
    Spokane, Washington 99204, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2008, a primary completion of Nov 2008 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2011, 2 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2008
First posted
Feb 11, 2008
Start
Feb 2008
Primary completionActual
Nov 2008
CompletionActual
Dec 2008
Results first posted
Apr 19, 2011
Last update
Apr 22, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00612573
Lead sponsor
Warner Chilcott
Responsible party
Sponsor
First posted
Feb 11, 2008
Start date
Feb 2008
Primary completion
Nov 2008
Completion
Dec 2008
Results posted
Apr 19, 2011
Last update
Apr 22, 2013

Study contacts

Angelo Secci, MD
study director · Warner Chilcott

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Doxycycline

Start the discussion